Literature DB >> 29653687

Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.

Denise Uyar1, Jamie Neary2, Amy Monroe3, Melodee Nugent4, Pippa Simpson4, Jennifer L Geurts5.   

Abstract

OBJECTIVE: The National Comprehensive Cancer Network recommends all women with ovarian cancer be offered genetic testing. Despite a decade of endorsement, many oncology practitioners have yet to make this a part of routine practice. Referral to genetic counseling and completion of genetic testing among patients at substantial risk of germline mutations are significantly lacking, adversely affecting patient care and squandering an opportunity to maximize cancer prevention efforts. This project determined the impact and feasibility of implementing a basic model for universal referral to genetic counseling and completion of genetic testing in women with a diagnosis of ovarian cancer in an academic gynecology oncology practice with access to electronic health records (EHRs).
METHODS: Patients diagnosed with ovarian cancer from January 2008 to November 2013 were retrospectively reviewed to determine the baseline referral rate for genetic counseling and testing completion in our practice. Implementation of a process change model combining provider training, patient education, enhanced electronic health record documentation and improved patient appointment scheduling strategies were implemented. We then prospectively collected data on all newly diagnosed ovarian cancer patients that had not already undergone genetic testing presenting from December 1, 2013 to November 30, 2016.
RESULTS: Genetic referral rates, genetic counseling and testing completion rates were markedly improved. Pre-implementation our genetic testing rate was 27% and post implementation our testing rate was 82% (p-value≤0.001).
CONCLUSIONS: Low cost interventions that target education of both providers and patients regarding the importance of genetic testing along with utilization of the EHR and streamlined patient appointment services can significantly increase rates of genetic testing completion.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gynecologic oncology; Ovarian cancer; Quality improvement; Universal genetic testing

Mesh:

Year:  2018        PMID: 29653687     DOI: 10.1016/j.ygyno.2018.03.059

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Disparities in gynecologic cancer genetics evaluation.

Authors:  Emily M Hinchcliff; Erica M Bednar; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2019-01-31       Impact factor: 5.482

2.  Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center.

Authors:  Adrianne R Mallen; Claire C Conley; Mary K Townsend; Ali Wells; Bernadette M Boac; Sarah Todd; Anjalika Gandhi; Michelle Kuznicki; Bianca M Augusto; McKenzie McIntyre; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil
Journal:  Clin Genet       Date:  2019-11-24       Impact factor: 4.438

3.  Genetic counseling referral for ovarian cancer patients: a call to action.

Authors:  Christine Garcia; Kara Harrison; Kari L Ring; Mackenzie W Sullivan; Lisa A Rauh; Susan C Modesitt
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

Review 4.  Addressing the routine failure to clinically identify monogenic cases of common disease.

Authors:  Michael F Murray; Muin J Khoury; Noura S Abul-Husn
Journal:  Genome Med       Date:  2022-06-07       Impact factor: 15.266

5.  Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology.

Authors:  Rosie O'Shea; Nicole M Rankin; Maira Kentwell; Margaret Gleeson; Katherine M Tucker; Heather Hampel; Natalie Taylor; Sarah Lewis
Journal:  Eur J Hum Genet       Date:  2021-04-02       Impact factor: 4.246

6.  Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.

Authors:  Janet R Vos; Ingrid E Fakkert; Joanne A de Hullu; Anne M van Altena; Aisha S Sie; Hicham Ouchene; Riki W Willems; Iris D Nagtegaal; Marjolijn C J Jongmans; Arjen R Mensenkamp; Gwendolyn H Woldringh; Johan Bulten; Edward M Leter; C Marleen Kets; Michiel Simons; Marjolijn J L Ligtenberg; Nicoline Hoogerbrugge
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

Review 7.  Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.

Authors:  Lindsey McAlarnen; Kristen Stearns; Denise Uyar
Journal:  Appl Clin Genet       Date:  2021-01-14

8.  "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.

Authors:  Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil
Journal:  Support Care Cancer       Date:  2020-09-25       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.